See the DrugPatentWatch profile for aclidinium
How long does the aclidinium bromide patent last in Europe?
Aclidinium bromide is protected by a set of patents (and related extensions) rather than a single uniform “end date” across Europe, so the effective remaining availability depends on which specific patent you mean (the original drug patent vs. later formulation/process patents and any supplementary protection certificate, if granted). The information needed to state an exact expiration date is not provided in the available sources here, so a precise European end date can’t be confirmed from the given material.
What changes the patent end date in Europe (SPC, patent types, and approval history)?
In Europe, the practical time left for market exclusivity is often determined by:
- the primary patent term for the active ingredient,
- whether a Supplementary Protection Certificate (SPC) was granted to extend protection tied to the first marketing authorization,
- and whether any later patents cover specific aspects such as formulations, combinations, or manufacturing processes.
Because those elements can differ by jurisdiction and by which patent family is being referenced, “how long is available” can produce different answers.
What you should check to get the exact expiry for aclidinium bromide in Europe
To find the exact patent/extension expiry date relevant to aclidinium bromide in Europe, you generally need:
- the specific patent family number or publication (for example, EP patent(s) covering aclidinium bromide),
- the relevant SPC data (if an SPC exists for the drug and in which country),
- and the first marketing authorization date used for the SPC calculation.
These details are typically obtained from patent/SPC registers (for example, by searching the EP family in the relevant national or European patent/SPC database and matching it to the approved product).
If you mean “when can generics/biosimilars enter,” is it the same as patent expiry?
Not necessarily. Even when patents expire, additional exclusivity periods (depending on regulatory and national rules) and remaining patents in other jurisdictions or for different claim scopes can delay generic entry. So the legal ability to market a competing product depends on the full patent landscape, not just the earliest patent expiry.
Can you tell which “patent” you’re referring to so I can give a date?
If you share either:
- the specific EP patent number(s) you mean, or
- the drug product/brand name and the country you care about (e.g., UK vs. Germany vs. France), or
- whether you mean the SPC expiry or the active-ingredient patent expiry,
I can help pin down the exact timeline for that specific protection type in Europe.